Business Context and Reporting Period
The source text is an Aileron Therapeutics, Inc. Form 10-K for the fiscal year ended December 31, 2019, filed March 30, 2020. The request identifies Rein Therapeutics, Inc.; this appears inconsistent with the filing, which identifies Aileron Therapeutics, Inc., ticker ALRN.
Aileron was a clinical-stage biopharmaceutical company developing stabilized cell-permeating peptides for oncology. Its lead candidate, ALRN-6924, targeted the p53 pathway and was being evaluated both as a chemotherapy-related myelopreservation agent and as an anti-cancer therapy.
Financial Metrics
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $17.7 million | $18.4 million | Down $0.8 million |
| General and administrative expense | $12.3 million | $13.5 million | Down $1.2 million |
| Total operating expenses | $30.0 million | $31.9 million | Down $1.9 million |
| Net loss | $29.4 million | $31.5 million | Loss narrowed by $2.2 million |
| Net loss per share | $1.20 | $2.14 | Improved, partly reflecting higher share count |
| Cash used in operating activities | $26.5 million | $27.9 million | Use decreased by $1.5 million |
| Cash, cash equivalents and investments at year-end | $18.3 million | $20.7 million | Down $2.4 million |
| Accumulated deficit | $198.1 million | $168.5 million | Increased by $29.6 million |
Year-end cash and cash equivalents were $5.3 million, with $13.0 million of short-term investments and $0.6 million of restricted cash. Total liabilities were $10.4 million, consisting primarily of operating lease liabilities and current operating obligations; the prior-year construction financing liability was eliminated upon adoption of the new lease standard. The filing does not report conventional funded debt at December 31, 2019.
Net cash provided by financing activities was $24.0 million, principally from the April 2019 private placement. The company issued common stock and warrants for gross proceeds of approximately $26.0 million and received approximately $23.8 million after issuance costs. Shares outstanding increased to 27.8 million from 14.7 million at year-end 2018.
Material Changes Versus the Prior Comparable Period
- R&D expense declined modestly, although spending on ALRN-6924 increased by approximately $0.6 million to $11.3 million. Lower employee, facility and other development costs more than offset increased clinical-trial costs.
- R&D headcount declined to seven at December 31, 2019 from 16 at December 31, 2018. Total full-time employees were 13 at year-end.
- G&A expense decreased primarily because 2018 included approximately $1.1 million related to a former chief executive officer’s separation agreement; legal costs also declined.
- The company initiated a Phase 1b/2 trial of ALRN-6924 as a myelopreservation agent in small-cell lung cancer patients receiving topotecan in September 2019.
- The company expanded its Phase 2a ALRN-6924/palbociclib trial from 25 to up to 35 patients after preliminary data showed median progression-free survival of 4.4 months in a subset of previously treated MDM2-amplified liposarcoma patients.
- Adoption of ASC 842 converted the headquarters lease to an operating right-of-use asset and lease liability and removed the prior construction financing liability.
Guidance, Outlook, Commentary and Risks
- Preliminary Phase 1b data from 11 patients in the first two dose cohorts showed a protective effect against severe thrombocytopenia and anemia, but not neutropenia. The data remained preliminary and were not definitive evidence of efficacy.
- Management expected to report dose- and schedule-optimization data from the myelopreservation trial in the fourth quarter of 2020, subject to enrollment delays from COVID-19.
- In March 2020, management shifted focus exclusively to myelopreservation, suspended or planned to suspend further development of the ALRN-6924/palbociclib combination and other anti-cancer indications, and began reducing operating expenses. Potential personnel reductions and elimination of planned studies and advisory services were contemplated.
- Based on the December 31, 2019 cash position and its then-current plan, management expected funding into the first quarter of 2021. However, management and the auditor reported substantial doubt about the company’s ability to continue as a going concern because available resources were not expected to fund operations for at least 12 months from the financial-statement issuance date.
- Additional equity financing, collaborations, licensing arrangements or strategic transactions were considered necessary, but no committed external funding source existed. Future financing could dilute shareholders or require the company to relinquish rights.
- COVID-19 created risks to clinical-site operations, patient enrollment, suppliers, manufacturing and access to capital. The pandemic had already delayed enrollment and could further delay clinical milestones.
- The company relied on a single contract manufacturer for ALRN-6924 active pharmaceutical ingredient and had no redundant supply arrangement. It also relied on third parties for clinical research, manufacturing, fill-and-finish, storage and distribution.
- The stock had transferred from Nasdaq Global Market to Nasdaq Capital Market after a bid-price deficiency. Nasdaq granted until July 6, 2020 to regain compliance with the $1.00 minimum bid-price requirement; a reverse stock split was identified as a possible remedy.
- ALRN-6924 remained investigational, no product had been approved or commercialized, and the company had never generated product-sale revenue. Regulatory approval, clinical efficacy, safety, manufacturing, companion-diagnostic and competitive risks remained substantial.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for Aileron Therapeutics, Inc., not Rein Therapeutics, Inc.
- Review the going-concern qualification and the company’s subsequent financing, restructuring and liquidity developments after March 30, 2020.
- Verify the status and final results of the ALRN-6924 myelopreservation trial, including effects on anemia, thrombocytopenia and neutropenia.
- Verify whether the ALRN-6924/palbociclib program was formally terminated and review the final progression-free-survival and safety results.
- Assess dilution from the 2019 financing, outstanding warrants, stock options and any later equity offerings.
- Check subsequent Nasdaq listing compliance and whether a reverse stock split or delisting occurred.
- Review COVID-19 effects on enrollment, clinical timelines, manufacturing supply and operating-expense reductions.
- Evaluate patent-license obligations, including milestone payments, royalties and the historical diligence dispute involving Harvard and Dana-Farber.